Real-World Outcomes of Belinostat in Relapsed Refractory T-Cell Lymphomas: A Report from the Lymphoma Study Group of Turkish Society of Hematology

Background: T-cell lymphomas (TCLs) constitute a heterogeneous group of mature T-cell neoplasms characterized by aggressive clinical behavior and poor outcomes, particularly in the relapsed/refractory (R/R) setting. Belinostat is a pan-HDAC inhibitor approved for R/R peripheral T-cell lymphomas. In this retrospective study, we analyze the real-world outcomes of single-agent belinostat in Turkish patients with R/R TCLs. Methods: Patients with R/R TCLs across Turkey who received at least one course of belinostat were included in the study. The primary end point was the overall response rate (ORR). The secondary end points included progression-free survival (PFS), overall survival (OS) and duration of response (DOR). Results: A total of 59 patients with R/R TCL were enrolled in the study, with a median age of 62 years. The median number of previous lines of therapy before belinostat was 2.5. The ORR for belinostat was 30.5% in the overall study cohort. Response assessment was available in 53 patients, among whom the ORR was 34% (18/53). The median PFS was 3 months. The median OS was 12 months, and the median DOR was not reached in responders. At least one adverse event occurred in 39.0% of patients. Conclusions: Belinostat produced objective responses in a subset of patients. These findings support belinostat as a potential individualized treatment option rather than a broadly effective standard for all patients with R/R TCLs. This multicenter real-world study demonstrates that the observed response rates closely mirror those reported in prospective clinical trials, confirming the reproducibility of belinostat efficacy in routine clinical practice.

Authors

Institutions

Publication Details

Journal
Journal of Clinical Medicine
Published
2026-08-17
DOI
https://doi.org/10.3390/jcm15166350
Primary Topic
Histone Deacetylase Inhibitors Research
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Real-World Outcomes of Belinostat in Relapsed Refractory T-Cell Lymphomas: A Report from the Lymphoma Study Group of Turkish Society of Hematology

Turgay Ulaş, Burak Devecı, Esra Terzi Demirsoy, Hüseyin Saffet Beköz et al.
Journal of Clinical Medicine
Histone Deacetylase Inhibitors Research
article

Real-World Outcomes of Belinostat in Relapsed Refractory T-Cell Lymphomas: A Report from the Lymphoma Study Group of Turkish Society of Hematology

Turgay Ulaş, Burak Devecı, Esra Terzi Demirsoy, Hüseyin Saffet Beköz, Fatma Keklik Karadağ, Işık Atagündüz, Mehmet Sönmez, Tayfur Toptaş, Süreyya Yiğit Kaya, Ayşe Tülin Tuğlular, Meral Uluköylü Mengüç, Gülçin Miyase Sönmez, Fazıl Çağrı Hunutlu, Fatma Arıkan, Fahir Özkalemkaş, Pelin Aytan, Volkan Karakuş, Gülsüm Özet, Selin Küçükyurt, Ahmet Kürşad Güneş, Metban Mastanzade, Emel İşleyen, Selami Koçak Toprak, Mustafa Nuri Yenerel, Figen Atalay, Özgür Mehtap, Ayşe Uysal, Fatma Aykaş, Melda Cömert, Deniz Şahin, Muhlis Cem Ar, Güray Saydam, Vildan Özkocaman, Umut Yılmaz, Esin Oguz Kozan, Zehra Akşit Bozkına, TURHAN KÖKSAL, Hulya Odluyurt, Mustafa Cabuk, Bugse Gulec Zengin
article en

Abstract

Background: T-cell lymphomas (TCLs) constitute a heterogeneous group of mature T-cell neoplasms characterized by aggressive clinical behavior and poor outcomes, particularly in the relapsed/refractory (R/R) setting. Belinostat is a pan-HDAC inhibitor approved for R/R peripheral T-cell lymphomas. In this retrospective study, we analyze the real-world outcomes of single-agent belinostat in Turkish patients with R/R TCLs. Methods: Patients with R/R TCLs across Turkey who received at least one course of belinostat were included in the study. The primary end point was the overall response rate (ORR). The secondary end points included progression-free survival (PFS), overall survival (OS) and duration of response (DOR). Results: A total of 59 patients with R/R TCL were enrolled in the study, with a median age of 62 years. The median number of previous lines of therapy before belinostat was 2.5. The ORR for belinostat was 30.5% in the overall study cohort. Response assessment was available in 53 patients, among whom the ORR was 34% (18/53). The median PFS was 3 months. The median OS was 12 months, and the median DOR was not reached in responders. At least one adverse event occurred in 39.0% of patients. Conclusions: Belinostat produced objective responses in a subset of patients. These findings support belinostat as a potential individualized treatment option rather than a broadly effective standard for all patients with R/R TCLs. This multicenter real-world study demonstrates that the observed response rates closely mirror those reported in prospective clinical trials, confirming the reproducibility of belinostat efficacy in routine clinical practice.

Journal of Clinical MedicineVol. 15(16)
Yeditepe University (TR), Bursa Uludağ Üni̇versi̇tesi̇ (TR), Ankara University (TR), Karadeniz Technical University (TR), Bilkent University (TR), University of Health Science (KH), Usak University (TR), Haliç University (TR), Istanbul Medipol University (TR), Ege University (TR), Gülhane Askerî Tıp Akademisi (TR), Ankara Onkoloji Eğitim ve Araştırma Hastanesi (TR), Antalya Eğitim ve Araştırma Hastanesi (TR), Istanbul University-Cerrahpaşa (TR), Başkent University Hospital (TR), Sağlık Bilimleri Üniversitesi (TR), Antalya IVF (TR), Mersin Üniversitesi (TR), Kocaeli Üniversitesi (TR), Istanbul University (TR), Marmara University (TR)
No poverty
Openalex Percentile: Top 16%
Histone Deacetylase Inhibitors Research
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.